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Background: The role of ovarian reserve markers as predictors of the controlled ovarian stimulation (COS) response
in intracytoplasmic sperm injection (ICSI) cycles in women with endometriosis has been much debated. The aim of
the present study is to assess the predictability of ovarian reserve markers for the number of mature oocytes (MII)
retrieved and to assess the pregnancy rate and live birth rate in women with advanced endometriosis.
Methods: Two hundred eighty-five infertile women who had laparoscopy followed by a first ICSI cycle were
recruited in this prospective study. One hundred ten patients were diagnosed with endometriosis stage III-IV (group
1), and 175 patients had no endometriosis (group II). Sixty-three patients in group 1 had no history of previous
endometrioma surgery (group Ia), and 47 patients had a history of previous endometrioma surgery (group Ib).
Results: The number of mature oocytes retrieved was significantly lower in women with advanced endometriosis
than in women with no endometriosis. The number of mature oocytes retrieved in women with and without
endometriosis was best predicted by antral follicle count (AFC) and age, whereas only AFC was a predictor in
women with previous endometrioma surgery (odds ratio: 0.49; 95% confidence interval: 0.13-0.60). Women with
endometriosis had a lower rate of live births than the control group, but this difference was not statistically
significant; the number of live births was significantly lower in those with previous endometrioma surgery.
Conclusions: The best predictor of the COS response in ICSI was AFC, followed by age. Women receiving ICSI
following surgery for ovarian endometrioma had a poorer clinical outcome and lower rate of live births compared
with those with endometriosis but no previous surgery and the control group.
Keywords: Stage III-IV endometriosis, Antral follicle count (AFC), Mature oocyte, Intracytoplasmic sperm injection
(ICSI), Live birth rateBackground
Endometriosis is benign but can be a debilitating
gynecological disorder and commonly presents with pain
and infertility [1]. The exact relationship between endo-
metriosis and infertility remains unclear; surgical find-
ings often do not correlate with fertility potential, nor do
they predict therapeutic response [2]. Endometriosis is a
common gynecological disorder that occurs in 6-10% of
the female population and is more frequent (25-40%) in
infertile women [3]. The reasons for this decreased* Correspondence: safiya.wahd@yahoo.com
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may include anatomical distortion, the toxic influence of
peritoneal fluid, decreased oocyte or embryo quality, de-
fective endometrial receptivity or diminished ovarian re-
serve [4]. The use of assessment of ovarian reserve in
women with endometriosis undergoing controlled ovarian
stimulation (COS) for assisted reproductive technique
(ART) has been controversial. Women with endometriosis
have been reported to have a lower ovarian reserve and
higher basal serum FSH level than their age-matched con-
trols [5,6]. Other studies suggested that ovarian reserve
markers may behave differently in women with and with-
out endometriosis [7,8]. The adverse effect of endome-
trioma surgery on ovarian reserve parameters, includingtd. This is an Open Access article distributed under the terms of the Creative
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ports in which endometriosis was surgically confirmed re-
ported lower serum anti-Müllerian hormone (AMH)
levels in the case of severe endometriosis r-AFS stages III
and IV [11]. The presence of endometriosis, particularly
ovarian endometrioma, in women undergoing ART has
been reported to reduce the response to COS [12,13]. Al-
Azemi et al. demonstrated that despite higher doses of go-
nadotropins, fewer oocytes were retrieved in ovarian
endometriosis cases; this phenomenon was amplified over
successive ART attempts [14]. However, not all investiga-
tors have found that COS yields were decreased with
endometrioma [15,16]. A meta-analysis of 22 studies re-
ported a lower chance of pregnancy for patients with
endometriosis compared to patients with tubal disease
(odds ratio: 0.56; 95% CI: 0.44-0.70) [8]. Others have re-
ported no adverse impact of endometriosis on in vitro
fertilization (IVF) outcomes compared with other infertil-
ity causes [17]. The aim of the present study was to evalu-
ate the predictability of AFC, serum AMH, FSH, and age
as predictors of COS response in patients receiving their
first ICSI cycle, with laparoscopically diagnosed and histo-
logically confirmed endometriosis with and without endo-
metrioma surgery compared with controls. We further
evaluated the impact of endometriosis and previous sur-
gery on clinical outcome.
Methods
Study subjects and design
A prospective, cross-sectional study was conducted on
460 infertile women to classify them through laparos-
copy according to the presence of endometriosis: those
with endometriosis represented the exposed group, and
those without endometriosis represented the unexposed
group. This study was conducted at the Maternity Teach-
ing Hospital Fertility Centre (MTHFC), Erbil, Kurdistan
region, Iraq, from July 1, 2011 to May 1, 2013. All ICSI cy-
cles were performed at MTHFC, which is the only public
maternity hospital in the city. The center was established
in April 2010 and is the main referral center for infertility
in Erbil. Women with a history of infertility are referred to
the fertility outpatient clinic, where they are investigated
and managed. The standard infertility investigation in our
center includes female medical history, clinical examin-
ation, gynecological ultrasound, and 2–3 day blood ana-
lysis for FSH, LH, estradiol, prolactin, TSH and AMH.
Serum progesterone was measured in the midluteal phase
of the menstrual cycle for assessment of ovulation. The
serum samples were frozen and stored for future ana-
lysis. AMH was measured with an ultrasensitive enzyme-
linked immunosorbent assay ELISA (AMH Gen II ELISA,
Beckman-Coulter, Inc, 250 S. Kraemer Blvd, Brea, CA
92821 U.S.A.). The lowest detection rate limit and intra-
and inter-assay variation coefficients were 0.03 ng/mL,3.4%, and 7.7%, respectively. The unit of measurement for
AMH used was ng/mL (1 ng/mL = 7.14 pmol/L). Ovarian
ultrasound scanning was performed to evaluate the num-
ber and size of antral follicles between 2–10 mm. Antral
follicle count involves counting the resting follicles present
on both ovaries at the beginning of the proliferative phase
of the menstrual cycle by transvaginal ultrasound. All the
scans were performed by a single operator on a GE p3
(LOGIG P3, GE Healthcare Wisconsin, USA) equipped
with a 6.5 MHz endovaginal probe (probe destination
8CS/E8C). A total of 460 women underwent diagnostic
laparoscopy at MTHFC as part of their fertility assessment
before starting treatment. At MTHFC, we recommend
laparoscopy for all women with 1) infertility for at least
3 years who have regular menstrual cycles (variation 21–
35 days) and whose partners have a normal semen ana-
lysis, 2) those with abnormal or inconclusive HSG 3) and
those who had previous laparoscopy or laparotomy for be-
nign gynecological conditions. All laparoscopies were per-
formed by or in the presence of the first author. When
present, the extent of endometriosis was staged surgically
according to the American Society for Reproductive Medi-
cine classification of endometriosis [18]. The inclusion cri-
teria of this study were as follows: 1) women receiving
their first cycle of ICSI, 2) infertility associated with endo-
metriosis stages III or IV, 3) infertile women with no visual
endometriotic lesion as a control group, 4) the absence of
polycystic ovarian syndrome (PCOS), and 5) the absence
of other endocrine disease (thyroid disease, diabetes melli-
tus, Cushing’s syndrome). The final study population con-
sisted of 110 women with endometriosis as the study
group (group I). The control group (group II) included
175 women undergoing ICSI cycles for infertility not re-
lated to endometriosis, The control group were women
with tubal factor (47.4%), unexplained infertility (37.7%)
and (14.8%) women with mild to moderate male factor in-
fertility. All of them were surgically confirmed for the ab-
sence of endometriosis. Women with endometriosis 10%
of them had mild to moderate male factor infertility. No
severe male factor infertility was found a cross all groups.
Women with endometriosis were further classified ac-
cording to their surgical history: group Ia with no prior
endometrioma surgery (n = 63) and group Ib with a
prior history of endometrioma surgery (n = 47). Only
women undergoing their first ART cycle were included
in the study.
Ovarian stimulation protocol
COS was conducted according to a down-regulation
protocol, which was achieved by subcutaneously (s.c.)
administering 0.1 mg triptorelin acetate (Decapeptyl,
Ferring Gmbh, D-24109 Kiel, Germany) daily starting
from the midluteal phase of the previous menstrual
cycle until the day of human chorionic gonadotropin
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from day 2 or 3 of the subsequent cycle if follicular di-
ameters did not exceed 10 mm and the serum estradiol
(E2) level was ≤ 50 pg/mL. Patients received a daily starting
dosage of 150 to 300 IU of recombinant follicle-stimulating
hormone (r-FSH, Gonal-F, Serono Laboratories, Aubonne,
Switzerland) s.c. that was individually chosen according to
age, body mass index (BMI), basal FSH, and basal AFC.
From day 6, the rFSH dose was adjusted according to
the ovarian response. When at least two leading follicles
reached 18 mm diameter, s.c. injection of 10,000 IU
human chorionic gonadotropin (Choriomon, IBSA,
Lugano, Switzerland) was administered, and transvagi-
nal ultrasound-guided oocyte retrieval was scheduled
for 36 hours later. Intracytoplasmic sperm injection was
performed in all cases because the aim of the center was
to minimize the incidence of fertilization failure and to
maximize the fertilization rate. This policy aided the
study in establishing fertilization uniformity and exam-
ining the oocytes for maturity. In Erbil and throughout
Iraq, IVF/ICSI treatment is not covered by government
funding or private insurance; the financial burden has
thus forced patients and clinicians to agree to transfer a
larger number of embryos than is accepted in many
countries. Therefore, the average number of transferred
embryos was 3–4. Embryo transfer was performed on
day 2 or 3 after oocyte retrieval. Luteal phase support
was provided the day after ovum retrieval with a Cyclogest
pessary (Actavis, UK) administering 400 mg progesterone
daily in addition to 10 mg oral dydrogesterone (Duphaston,
Solvay Pharma Istanbul) three times daily. A serum hCG
level >20 IU/L was defined as a pregnancy. A transient in-
crease in hCG was defined as a biochemical pregnancy. In
all other pregnancies, an ultrasound scan was performed
5–7 weeks after embryo transfer (ET). Clinical pregnancy
is defined by ultrasound visualization of an intra-uterine
gestational sac and embryonic pole with a heartbeat. All
pregnant women were asked to report back, in writing,
the outcomes; if women did not report back, they were
phoned to inquire about the pregnancy and birth out-
come. The primary outcomes were the number of ma-
ture oocytes retrieved in the endometriosis patients and
the control group, pregnancy rate and live birth rate.
The secondary outcomes were the total gonadotropin
dose (IU), number of embryos formed and number of
good-quality embryos (embryos with blastomers of
equal size and no cytoplasmic fragmentation, or < 20%
fragmentation).
The Research Ethics Committee of Hawler Medical
University, College of Medicine, approved the study
proposal on June 24, 2011, (reference number 1/24-06-
2011). Informed consent was obtained from all partici-
pants after they were fully informed of the aim, process
and confidentiality of the study.Statistical analysis
Data were analyzed using the Statistical Package for So-
cial Sciences (SPSS, version 19). One-way analysis of
variance (ANOVA) was used to compare among means
of three or more groups. A post hoc test (LSD) was used
to determine whether the difference between two groups
was significant (conducted after the ANOVA). A chi
square test of association was used to compare between
proportions. When the expected count of more than 20%
of the cells of the table was less than 5, Fisher’s exact test
was used. Multiple regressions were used when the
dependent variable was numerical. The power of the study
was estimated to be 80% according to the computer pro-
gram ‘power and sample size estimation’ version 3.0.43. A
‘P’ value of ≤0.05 was considered statistically significant.
Results
Figure 1: is the total inclusion flow chart.
The mean age of all the studied groups was 32.72 ±
5.76 years. The groups were comparable in age, infertil-
ity duration and basal day 3 FSH and estradiol levels
(Table 1), but group II had a higher BMI. The AFC was
lower in group Ib (9.09 ± 3.07) and group Ia (10.75 ± 3.07)
compared with the control group (12.39 ± 4.17) (P < 0.001).
The AMH level was lower in group Ib (1.06 ± 0.85) than in
group Ia (1.86 ± 1.03, P < 0.003) and group II (2.19 ± 1.57,
P < 0.001).
Groups Ia and Ib had significantly fewer mature oo-
cytes at ovum retrieval than the control group (5.63 ±
2.74, 4.71 ± 2.29 and 6.92 ± 4.47, respectively; P < 0.001)
despite requiring a higher dose of gonadotropin (Table 2),
whereas the number of embryos developed was similar
among the groups. The fertilization rate was lower in group
Ib than in the other groups, but this difference was not sta-
tistically significant. The pregnancy rate, clinical pregnancy
rate and live birth rate per cycle following ICSI treatment
in group Ia were 36.5%, 27% and 23.8%, respectively, lower
than in the other two groups, but failed to reach statistical
significance when compared with the control group (group
II), with values of 44.6%, 36.6% and 29.1%, respectively. The
live birth rate (8.5%) was significantly lower following ICSI
in women who had previous endometrioma surgery (group
Ib) than in the control group and group Ia.
Multiple linear regression analyses were performed to
study the major independent factors (age, AFC, AMH,
FSH and estradiol) for the number of mature oocytes re-
trieved, which was used as the dependent variable
(Table 3). The largest influencing independent factor was
AFC in women with endometriosis stage III-IV (OR =
0.589, 95% CI = 0.269–0.786). The second most influential
independent factor was age (OR = 0.257; 95% CI = 0.006–
0.260). In women with prior endometrioma surgery, the
only influencing independent factor was AFC (OR = 0.497;
95% CI = 0.134–0.605) and no age influence was found.
Figure 1 Patient inclusion flowchart.
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ence on the number of mature oocytes retrieved in ei-
ther group.
In women with no endometriosis, serum AMH, basal
FSH, and estradiol had no influence on the number of ma-
ture oocytes retrieved. For the prediction of the number of
mature oocytes according to multiple regression analysis,
AFC remained the best predictor (OR = 0.596; 95% CI =
0.470–0.816), followed by age (OR = 0.151; 95% CI =
0.008–0.219).Table 1 Clinical characteristics of women with endometriosis
without endometriosis
Parameters Stage III and IV endometriosis, n = 110
eIa-No previous
surgery, n = 63
Ib-Previous endometrioma
surgery, n = 47
Age (years) 32.67 ± 5.27 32.62 ± 5.63
Duration (years) 8.62(4.86) 7.32(5.05)
AFC 10.75 ± 3.07 9.09 ± 3.07
AMH (ng/mL)* 1.86 ± 1.03 1.06 ± 0.85
FSH (mIU/mL) 6.61 ± 2.56 6.97 ± 2.75
E2 (pg/mL) 38.98 ± 17.34 35.93 ± 16.01
BMI (kg/m2) 25.74 ± 4.27 26.25 ± 4.11
AFC: antral follicle count; AMH: Anti-Müllerian hormone; *(Conversion factor to pmoIn 9 patients with previous endometrioma surgery
a ≤4 cm endometrioma at the time of oocyte retrieval
was noted. In 3 women the endometrioma was acciden-
tally punctured at the time of ovum pick up. In one pa-
tient after failure of the cycle she developed pelvic abscess.
Discussion
AMH has gained wide popularity as an ovarian reserve
marker because it offers several advantages compared
with other markers, it is stable throughout the menstrualstage III-IV, previous endometrioma surgery and infertility
II-No
ndometriosis n = 175
Overall
P value
P IaXIb P IaXII P IbXII
32.77 ± 5.99 0.983
8.32(5.15) 0.381
12.39 ± 4.17 <0.001 0.24 0.003 <0.001
2.19 ± 1.57 <0.001 0.003 0.103 <0.001
6.42 ± 2.51 0.422
40.13 ± 18.44 0.357
29.66 ± 4.86 <0.001 0.571 <0.001 <0.001
l/L X7.14); E2: estradiol; BMI: body mass index.
Table 2 ART outcomes of women with endometriosis stage III-IV, previous endometrioma surgery and infertility
without endometriosis





P IaXIb p IaXII P IbXII
Ia-No previous surgery, n = 63 Ib-Previous surgery, n = 47
Total gonal-F dose, IU 2622 ± 543 2765 ± 552 2307 ± 685 <0.001a 0.253 0.001 <0.001
No. of stimulation days 10.98 ± 1.42 10.76 ± 1.54 10.99 ± 1.67 0.663a
Estradiol on day of HCG 1350 ± 849 1182 ± 547 1479 ± 784 0.065a
No. of oocytes retrieved 6.97 ± 3.29 5.96 ± 2.40 8.82 ± 5.13 <0.001a 0.245 0.005 0.001
No. of mature oocytes 5.63 ± 2.74 4.71 ± 2.29 6.92 ± 4.47 0.001a 0.228 0.027 <0.001
Fertilization rate 0.75 ± 0.18 0.71 ± 0.19 0.73 ± 0.25 0.741a
Embryo no. 4.15 ± 2.08 3.36 ± 1.68 5.08 ± 4.00 0.005a 0.234 0.068 0.234
High-quality embryo 3.06 ± 1.42 2.44 ± 1.14 3.31 ± 2.47 0.071a
No. of ET 3.10 ± 1.21 2.79 ± 1.25 3.05 ± 1.10 0.317a
Implantation rate 0.42 ± 0.22 0.37 ± 0.12 0.40 ± 0.16 0.636a
PR/cycle 23/63(36.5) 10/47(21.3) 78/175(44.6) 0.013b 0.096 0.300 0.004
Biochemical pregnancy 6/23(26.1) 4/10(40.0) 14/78(17.9) 0.289b
Clinical PR/cycle 17/63(27.0) 6/47(12.8) 64/175(36.6) 0.006b 0.097 0.215 0.002
Live birth rate/cycle 15/63(23.8) 4/47(8.5) 51/175(29.1) 0.013b 0.043 0.512 0.004
PR/ET 23/60(38.3) 10/44(22.7) 78/170(45.9) 0.019b 0.135 0.365 0.006
Clinical PR/ET 17/60(28.3) 6/44(13.6) 64/170(37.6) 0.008b 0.096 0.212 0.004
Live birth/ET 15/60(25.0) 4/44(9.1) 51/170(25.5) 0.017b 0.043 0.510 0.006
Mmultiple birth/live birth 4/15(26.7) 0/4(0) 11/51(21.6) 0.591b
Cancellation rate 3/63(4.8) 3/47(6.4) 5/175(2.9) 0.557b
aAnalysis of variance (ANOVA).
bChi-square test.
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apy usage [19-21]. In the current study, women with lap-
aroscopically confirmed stage III-IV endometriosis and
with a history of endometrioma surgery had a serum
AMH level that was significantly lower than in women
with no history of surgery for endometrioma and the
control group. This finding is in agreement with other
studies reporting on the adverse effect of endometrioma
surgery on the ovarian reserve [13,21-25]. Various expla-
nations of the effect of ovarian surgery on the ovarian re-
serve in endometriosis have been proposed. Bongioanni
et al. [26] and Matalliotakis et al. [13] stated that ovarian
destruction caused by surgery was the major reason. The
lack of a real plane of cleavage between the endometrium-
like stroma of the endometriotic cysts and the ovarian tis-
sue can lead to the removal of adjacent healthy ovarian
tissue, which may harm the ovarian reserve [27,28]. How-
ever, Kumbak et al. [29] compared ovarian endometriosis
and simple ovarian cysts to evaluate the space-occupying
effect on the ovary and concluded that the endometriosis
itself led to the decline of the ovarian reserve and the poor
response. However, some reports showed no differences in
ovarian reserve before or after endometrioma resection
[30,31]. In the current study, we observed that the basal
serum FSH level was the same between the study groups.Several studies have investigated ovarian reserve in endo-
metriosis. Lemos et al. [32] demonstrated that infertile pa-
tients with minimal or mild endometriosis exhibited
decreased serum AMH levels compared to a control group.
In that study, the two groups’ serum FSH levels did not dif-
fer. However, Hock et al. [7] reported a significant increase
in basal FSH levels in women with advanced endometri-
osis, supporting the idea of a progressive loss of ovarian
function as the disease advances. Furthermore, Barri et al.
[33] found that patients with endometriosis had a higher
FSH level and a lower AFC than patients with male-factor
infertility before any treatment, especially surgery. AFC has
been demonstrated to be a reliable marker of ovarian re-
serve because it correlates significantly with age-related fol-
licle count decline and with ovarian response to IVF
stimulation cycles [19,20]. In the current study, no signifi-
cant differences were found in AFC in women with a pre-
vious history of endometrioma surgery and no history of
endometrioma surgery. However, AFC was significantly
lower in both groups than the control group. Our finding
is in agreement with the systematic review and meta-
analyses performed by Muzii et al. [34], in which the ovar-
ian reserve evaluated with AFC was not reduced after sur-
gical treatment of an endometrioma and a lower AFC was
present in both those who had no previous surgery for
Table 3 Multiple linear regression analysis of possible determinants of mature oocytes retrieved in women with stage
III and IV endometriosis and control
Unstandardized coefficients Standardized coefficients T P 95% Confidence interval for B
B Std. error B Lower bound Upper bound
a-Factors predicting number of mature oocytes in endometriosis and no previous surgery
(Constant) −1.238 4.480 -.276 0.783 −10.236 7.761
Age (years) 0.133 0.063 0.257 2.103 0.040 0.006 0.260
AFC 0.528 0.129 0.589 4.098 0.000 0.269 0.786
AMH (ng/mL) 0.023 0.361 0.009 0.065 0.948 −0.701 0.748
FSH (mIU/mL) 0.118 0.122 0.103 0.966 0.339 −0.128 0.364
E2 (pg/mL) −0.013 0.015 −0.083 −0.858 0.395 −0.044 0.018
b-Factors predicting number of mature oocytes in women with previous endometrioma surgery
(Constant) -.223 2.924 −0.076 0.940 −6.160 5.714
Age (years) 0.049 0.071 0.117 0.684 0.498 −0.096 0.193
AFC 0.369 0.116 0.497 3.182 0.003 0.134 0.605
AMH (ng/mL) 0.246 0.347 0.091 0.709 0.483 −0.458 0.949
FSH (mIU/mL) 0.073 0.101 0.086 0.723 0.474 −0.132 0.279
E2 (pg/mL) −0.004 0.018 −0.028 −0.222 0.825 −0.040 0.032
c-Factors predicting number of mature oocytes in women without endometriosis
(Constant) −6.632 2.770 −2.394 0.018 −12.102 −1.161
Age (years) 0.114 0.054 0.151 2.121 0.035 0.008 0.219
AFC 0.643 0.088 0.596 7.341 0.000 0.470 0.816
AMH (ng/mL) 0.147 0.188 0.051 0.781 0.436 −0.224 0.517
FSH (mIU/mL) 0.089 0.096 0.049 0.922 0.358 −0.101 0.279
E2 (pg/mL) −0.021 0.013 −0.087 −1.672 0.096 −0.046 0.004
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These data may support the hypothesis that damage to
the ovarian tissue is already present before surgery and
is therefore caused by the disease itself rather than the
surgical procedure [35].
In our study, the response to ovarian stimulation with
gonadotropin in terms of the total dose and number of
retrieved oocytes differed between patients with ASRM III
and IV endometriosis and those with infertility without
endometriosis. This finding of an inferior ovarian response
in subjects with ASRM III-IV endometriosis confirms
prior reports [13,14,36,37]. We further concluded that in
women undergoing ICSI with stage III-IV endometriosis
with and without a history of endometrioma surgery, des-
pite higher gonadotropin stimulation, the ovarian response
was not influenced, as measured by number of oocytes re-
trieved. In women with extensive endometriosis with and
without endometrioma, reports on the outcome of ART,
including pregnancy rate and live birth rate, are also con-
flicting, with some suggesting poor outcomes [38,39] and
others suggesting comparable treatment outcomes [13,40].
The main finding of our study is that women receiving
their first ICSI treatment cycle, specifically those with
endometriosis ASRM III-IV, had comparable PRs and livebirth rates to women with no endometriosis, whereas the
pregnancy rate and live birth rate were significantly lower
only in women who had prior endometrioma surgery. Our
results are similar to those reported by Opoien et al. [41].
However, a meta-analysis showed that surgery for endo-
metrioma did not have any adverse effects on subsequent
responses to stimulation [42]. Furthermore, in a meta-
analysis of observational studies, it was concluded that the
PR after IVF was similar regardless of endometrioma sur-
gery [43]. Surgery for endometrioma can affect the ovarian
response to COS to the point of compromising the ART
outcome, even if embryo implantation rates are not af-
fected following ovarian suppression [44,45]. Poor quality
of oocytes has been suggested as one possible cause of in-
fertility in women with endometriosis as a result of higher
apoptotic incidence, more alterations of the cell cycle and
higher incidence of oxidative stress than in patients with
any other infertility cause [46]. In the current study, we
demonstrated that only AFC was most significant in pre-
dicting the ovarian response in women with previous
endometrioma surgery, followed by age. Serum AMH level
was not a significant predictor of the ovarian response.
This finding concurs with the result of Hock et al. [7], who
demonstrated that a progressive loss of ovarian reserve in
Wahd et al. Reproductive Biology and Endocrinology 2014, 12:120 Page 7 of 8
http://www.rbej.com/content/12/1/120women with increasing stages of endometriosis was inde-
pendent of age. However, Yoo et al. [5] reported that the
serum AMH represents a more useful ovarian response
marker in women with endometriosis than age or FSH,
whereas in our study, serum AMH did not predict the
ovarian response. Although AFC proved to be a useful pre-
dictor of stimulation outcome in IVF, there might be differ-
ences in AFC measurements among observers; in our
study, the AFC measurement had good reproducibility be-
cause there was only one sonographer. Therefore, inter-
observer variability did not have an impact on the results
of the current study.
The strength of our study lies in the selection of
women with endometriosis and the control group based
on strict surgical and histological criteria, using clinical
data collected prior to laparoscopy and having controls
that were all surgically examined to exclude asymptom-
atic endometriosis. We considered live birth as an end-
point, and all patients were receiving their first ICSI
cycle. All laparoscopy was performed by the same team
of doctors in the same hospital, and the measurement of
AFC was conducted by one sonographer in a single center
study. The primary limitation of the study is that in
women with previous endometrioma surgery, no informa-
tion was available regarding the size of the endometrioma
and the types of operations were not available or clearly
documented. The control group included several types of
infertility and this could have influenced the results.
Conclusions
For women with laparoscopically and histologically con-
firmed stage III-IV endometriosis receiving their first ICSI
cycle, serum AMH levels were significantly low only in
women with a previous history of endometrioma surgery,
whereas AFC was significantly lower in both groups of
endometriosis with and without a previous history of
endometrioma surgery compared with the control group.
Multivariate analysis confirmed that AFC represents the
most useful ovarian response marker to COS in all studied
groups, as the number of mature oocytes retrieved in-
creased with increasing AFC but decreased with increas-
ing age. The number of live births that followed the first
ICSI cycle, per cycle and per embryo transfer was lowest
in those who had previous surgery for endometrioma.
Randomized controlled trials will be more effective in es-
tablishing whether surgery for endometrioma influences
ART outcomes.
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